论文部分内容阅读
Systemically administered anticancer treatments were greatly limited by extensive side effects mainly due to nonspecific distributions in vivo and multidrug resistance in various tumors.A phospholipids-based in situ-forming gel platform has been developed for the concurrent delivery of doxorubicin (DOX) and bromotetrandrin (W198).